Haleon plc (NYSE:HLN) Shares Bought by Park Avenue Securities LLC

Park Avenue Securities LLC grew its holdings in Haleon plc (NYSE:HLN - Free Report) by 41.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 142,428 shares of the company's stock after acquiring an additional 41,807 shares during the quarter. Park Avenue Securities LLC's holdings in Haleon were worth $1,359,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Rhumbline Advisers boosted its stake in Haleon by 20.0% in the 2nd quarter. Rhumbline Advisers now owns 48,966 shares of the company's stock worth $404,000 after purchasing an additional 8,160 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Haleon by 2.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,007,458 shares of the company's stock worth $8,322,000 after buying an additional 24,673 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in shares of Haleon by 7.5% during the second quarter. Mercer Global Advisors Inc. ADV now owns 150,817 shares of the company's stock valued at $1,246,000 after buying an additional 10,577 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Haleon by 17.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 113,297 shares of the company's stock valued at $936,000 after buying an additional 17,138 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Haleon by 21.0% in the 2nd quarter. Blair William & Co. IL now owns 40,449 shares of the company's stock valued at $334,000 after acquiring an additional 7,020 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. UBS Group upgraded Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 8th. Finally, Morgan Stanley lowered shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.95.

Haleon Stock Performance

Shares of HLN stock traded up $0.05 on Monday, hitting $9.24. The company had a trading volume of 21,226,372 shares, compared to its average volume of 5,607,522. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a market cap of $41.80 billion, a P/E ratio of 27.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.29. The company has a 50-day moving average price of $9.54 and a 200-day moving average price of $9.71.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.